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Abstract
Background: The 13q deletion syndrome is a rare chromosome disorder associated with wide phenotypic spectrum,
which is related to size and location of the deleted region and includes intellectual disability, growth retardation,
craniofacial dysmorphisms, congenital malformations, and increased risk of retinoblastoma.
Case presentation: Here, we report on a teenage boy with a mild phenotype characterized by obesity, hyperactivity,
dysphagia, dysgraphia, sleep disturbance, and minor dysmorphic features (round face, bushy eyebrows, and stubby
hands). Array Comparative Genomic Hybridization on blood identified a mosaic 13q14.13-13q31.1 deletion, with a
mosaicism rate around 40%, which was confirmed by quantitative PCR and interphase Fluorescent In Situ Hybridization
(iFISH) on both blood genomic DNA and cultured/uncultured blood lymphocytes, respectively. Conversely, karyotype
analysis on blood estimated a mosaicism rate of 24% and iFISH on buccal smears revealed a borderline value of 0.4%,
suggesting the absence of 13q deletion in this cell line.
Conclusions: The comparison with previous patients carrying similar deletions informed that the proband clinical
presentation is the mildest reported to date, thus supporting the burden of mosaicism in modulating the phenotype
also in case of large chromosomal rearrangements. Characterization of further cases by in-depth mosaicism rate in
tissues with different embryonic origins might contribute in the future to a better definition of genotype-phenotype
correlation, including tumor risk.
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Background
The 13q deletion syndrome is a rare chromosome disorder
characterized by a wide phenotypic spectrum, depending
on size and location of the deleted region. Clinical features
include moderate to severe intellectual disability (ID),
growth retardation, craniofacial dysmorphisms, congenital
malformations, and increased risk of tumors, in particular
retinoblastoma [1–5]. On the basis of karyotype-phenotype
correlation, three patients groups have been distinguished.
Group 1 includes patients with proximal deletions
(13q12.2q31), who show mild or moderate ID, growth
retardation, distal limb anomalies, variable dysmorphic
features, and, possibly, retinoblastoma; Group 2 assembles
patients with deletions encompassing the 13q32 band and
characterized by severe ID and major malformations,
mostly affecting the brain; finally, Group 3 comprises pa-
tients with distal deletions involving bands 13q33q34, who
display severe ID without major malformations [3, 4, 6].
Prenatal diagnosis of 13q deletion syndrome has been
scarcely described in literature. Excluding cases with a
mosaic r(13) chromosome and those where 13q deletion
is the result of an unbalanced reciprocal translocation,
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up to now seventeen prenatally diagnosed patients have
been reported [7, 8], including one mosaic case [9].
While prenatal ultrasound examination is abnormal in
almost all the reported patients, with a high frequency of
brain anomalies likely due to the almost constant
involvement of the q32 band [7, 8], measurement of nu-
chal translucency (NT) in the first trimester has been
rarely recorded [7, 10]. However, as this parameter has
been always found increased when evaluated [7, 10], 13q
deletion syndrome has been added to the group of those
structural chromosomal abnormalities to be considered
early in pregnancy (11–14 weeks of gestation) by means
of ultrasound assessment [8].
Here, we report on a teenage boy with a mild pheno-
type who was found to carry a mosaic 13q14.13-13q31.1
deletion, including the retinoblastoma 1 (RB1) gene. The
comparison with previously described patients clarified
that his clinical presentation is the mildest reported to
date in association to a 13q deletion, and may be mainly
attributed to the mosaic status of the rearrangement. In
addition, the in-depth mosaicism rate characterization in
tissues with different embryonic origins (blood and buc-
cal epithelium) might contribute in the future to a better
definition of genotype-phenotype correlation, including
tumor risk. The mosaicism burden in modulating the
overall phenotype generally associated to constitutional
genetic defects is thus supported also in the case of large
chromosomal rearrangements.
Case presentation
Clinical report
The patient is a 16-year-old boy, born at term by natural
delivery from unrelated healthy parents. The mother and
father were 38 and 43 years old at time of birth. Prenatal
NT at ultrasound examination and karyotype on amnio-
cytes, performed because of advanced maternal age,
were referred as normal. Patient birth weight was 3950 g
(90th percentile), length 51 cm (50-75th p), and occipital
frontal circumference 34.5 cm (50-75th p). Apgar scores
were 9/9. The patient started walking autonomously at
13 months, pronounced his first words at 11 months,
and then has shown neither developmental delay (DD)
nor ID. Neuropsychological evaluation at 9 years using
WISC-III [11] evidenced mild learning disabilities,
namely dysgraphia. At the last follow-up at the age of
13, the phenotype was very mild, mainly characterized
by obesity (weight > 97th p), a normal height (150.5 cm,
50-75th p), hyperactivity, dysphagia, sleep disturbance,
and minor dysmorphic features such as round face,
bushy eyebrows, and stubby hands. Brain MRI and angi-
ography showed an altered signal near both the capsular
lenticular structures and the head of the caudate
nucleus, implying the presence of a hamartoma. He was
referred to our lab for Smith-Magenis syndrome
(SMS)-like phenotype without SMS molecular diagnosis
(neither a 17p11.2 deletion nor RAI1 mutations were
formerly identified).
Methods
High-resolution array-based Comparative Genomic
Hybridization (a-CGH) analysis was performed on gen-
omic blood DNA (gDNA) of the patient and his parents,
using the SurePrint G3 Human CGH Microarray Kit
2x400K in accordance with the manufacturer’s instruc-
tions (Agilent Technologies, Palo Alto, CA). Copy Num-
ber Variants (CNVs) were analyzed and mapped using
the Human Genome assembly GRCh37/hg19. The CNV
classification by clinical relevance was performed ac-
cording to the guidelines suggested by Miller et al. in
2010 [12] and successively by the American College of
Medical Genetics [13].
To estimate the mosaicism rate based on the
a-CGH result, the value of the 13q deletion average
log ratio (Rlog2) had been firstly considered. This
value is obtained from ADM-2 algorithm (Agilent
CytoGenomics v.3.0.6.6, Agilent Technologies) that
analyze copy numbers found in patient compared to
those found in controls. Using the formula 2Rlog2 the
unit ratio (R) between patient and controls was cal-
culated. Then, if 2 N and N are the copy number of
the target region in the not deleted and deleted 13q
cells respectively, and x is the percentage of cells
carrying the deletion, R can be calculated as follow:
R ¼ Patient copy numbers
Controls copy numbers
¼ ð100−xÞ2NþxN100ð2NÞ . Namely, in cells
without a deletion of the 13q target region ((100 − x)2N)
and in cells carrying a deletion (xN) the percentage of mo-
saicism for a deletion can be calculated as x = 2(1 − R)100.
To confirm a-CGH results, copy number quantifica-
tion by means of quantitative polymerase chain reaction
(qPCR, SYBR® Green methodology) was used. Primers
were selected within regions of unique non-repetitive
sequence using Primer3 software (http://bioinfo.ut.ee/
primer3-0.4.0/); a control amplicon was selected with
the same parameters in PCNT at 11q14.1. qPCR condi-
tions and primer sequences are available on request.
Standard curve using a dilution series with a control
sample mixed with a known non-mosaic deletion of 13q
was built up. Conventional cytogenetic analysis was
performed on 50 QFQ-banded metaphases obtained
from the proband’s peripheral blood lymphocytes using
standard procedures. The karyotype was described in
accordance with ISCN (2016) [14]. iFISH analysis was
performed on either peripheral blood lymphocytes culti-
vated for 72 h, peripheral uncultured blood lymphocytes,
and buccal epithelium using the AneuVysion® multicolor
probe LSI 13/21 (Abbott-Vysis, Chicago, IL), that con-
tains both a mixture of unique DNA sequences covering
Bestetti et al. Molecular Cytogenetics  (2018) 11:53 Page 2 of 8
RB1 at 13q14, and sequences complementary to the
D21S259, D21S341, and D21S342 loci within the
21q22.13q22.2 region. In particular, for iFISH analysis
on uncultured blood, lymphocytes ring was obtained
from Lithium Heparin tubes. The pellet was suspended
in a 3:1 methanol:acetic acid fixative solution and
dropped across a clean slide. For iFISH analysis on buc-
cal mucosa, the surface cells of both cheeks were first
scraped from the patient and two controls by using cyto-
brushes. The cells were then removed by agitation in a
1:1 methanol:acetic acid fixative solution for 10 min, and
the cell suspension was centrifuged at 1200 rpm for
10 min. The pellet was suspended in a 3:1 methanol:ace-
tic acid fixative solution and dropped across a clean
slide. The slides were checked with a phase microscope
for the presence of cells with adequate morphology. The
AneuVysion probe standard protocol was followed with
minor modifications. Overall, a total of 500 randomly
selected nuclei with both 21q control signals for each
tissue were analyzed in both the proband and two con-
trol samples. The control with the greatest number of
false-positive nuclei was used to determine the normal
cutoff. Beta inverse calculation using the Microsoft Excel
function, = BETAINV (Confidence level, false-positive
cells plus 1, number of cells analyzed) for a 95th confi-
dence limit and a total of 500 observations provided the
false positive cutoff values for each tissue [15].
Results
a-CGH analysis on patient’s whole blood genomic DNA
disclosed a rare ~ 40 Mb 13q14.13q31.1 mosaic deletion
(minimum interval, chr13:46,968,080-87,381,985, GRCh37/
hg19) as the only pathogenic CNV (http://www.ncbi.nlm.-
nih.gov/clinvar/, ClinVar accession number SCV000748
684), which affected 87 RefSeq genes (Fig. 1a). Somatic mo-
saicism was estimated at around 40% based on the a-CGH
hybridization profile shift and the corresponding log ratio
value (− 0.326) (Fig. 1a). The analysis of the parents
confirmed the deletion was de novo in origin.
To assess this mosaic deletion by independent techniques,
conventional cytogenetic and region-specific genomic ana-
lyses were performed. While karyotype analysis pointed out
Fig. 1 13q mosaic deletion identified in the patient. (a) Identification in the patient of a mosaic 40 Mb deletion at 13q14.13q31.1 using Agilent CGH 400 K
array. (b) Conventional cytogenetic analysis identified the chromosome del(13)(q14.13q31.1) carrying an interstitial deletion in 24% of the analyzed
metaphases. (c) qPCR estimation (red oval shape) of the deletion mosaicism rate by using both deletion specific probes and a reference mosaic scale
including different percentages of cells carrying a 13q deletion. (d, e) Commercial LSI13/21 probe yielded one hybridization signal specific for the RB1 locus
at 13q14.2 (green) in ~ 35% and 0.4% of patient’s lymphocytes (d) and buccal cells (e), respectively (arrow), and two signals specific of chromosome 21
(red) in all the analyzed nuclei
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a del(13)(q14.13q31.1) in 24% of the metaphases analyzed
(Fig. 1b), qPCR revealed about 40% of deleted cells (Fig. 1c),
consistent with the a-CGH results. Similarly, iFISH experi-
ments carried out on patient’s cultured/uncultured blood
lymphocytes confirmed the previous a-CGH results.
Namely, 13/500 and 10/500 nuclei with only one RB1 signal
were detected in cultured and uncultured controls’ lympho-
cytes, and the relative false positive cutoff of 4% and 3.3%
were applied to patient’s RB1 deleted nuclei from cultured
(195/500) and uncultured (186/500) lymphocytes,
leading to a final mosaicism rate of ~ 35% and ~ 34%,
respectively (Fig. 1d). A mosaicism underestimation
by conventional cytogenetic analysis due to the small
size of the sample analyzed was then supported. In-
deed, culture-dependent positive selection in favor of
dividing cells without the structural aberration has
been ruled out by iFISH experiments on both
cultured and uncultured lymphocytes that showed the
same results.
Contrary, the evaluation of mosaicism using iFISH on
buccal smears, which have an embryonic origin different
from blood, showed that 4.4% (22/500) of patient’s cells
carried the deletion (Fig. 1e). Based on a false-positive
cutoff of about 4% of the control nuclei (13/500), the
deletion on patient’s buccal smear cells was estimated as
0.4%, a borderline result suggesting the absence of 13q
deletion in this cell line.
Discussion and conclusions
According to the proposed 13q deletion classification
[1–6], the deletion identified in the patient falls in Group
1. Although the boy shares with 13q deletion syndrome
some neurological features such as sleep disorder, hyper-
activity, and learning disabilities, his clinical presentation
is definitely the mildest reported to date, as demonstrated
by the lack of ID, developmental and growth retardation,
peculiar dysmorphisms, major malformations, and tumors
(Table 1). This conceptually conflicts with the large size
(40 Mb) of the identified structural anomaly as demon-
strated by previously reported Group 1 deletions with
similar size to that described here, which have been
constantly associated to more severe clinical pictures
(Table 1) [16–21]. Therefore, the mosaic condition of the
deletion might likely explain the patient’s mild phenotype.
As known, the effect of chromosomal mosaicism on
the phenotype cannot be easily predicted as it depends
on the different proportions of cells carrying the abnor-
mality which may widely vary in tissues with different
embryonic origin, thus supporting the need to precisely
assess the mosaicism rate in as many tissues as possible.
To date just three cases of a mosaic 13q deletion have
been reported [9, 22, 23], although detailed clinical and
cytogenetic data are available for just one of them [9].
Widschwendeter and colleagues reported a case of a
25 weeks fetus presenting with multiple anomalies at
ultrasound examination, including severe cerebral
malformations. Prenatal diagnosis by rapid-FISH on
uncultured amniocytes and conventional cytogenetic
analysis from cord lymphocyte metaphases revealed a
del(13)(q13.3) in 18% of the investigated cells, whose
discovery led to the pregnancy termination [9]. Note-
worthy, despite the evidence of a quite low mosaic status
of the deletion in the tissues analyzed, a very severe
phenotype resulted in this case from a rearrangement in-
volving the 13q32 chromosomal segment, whose deletions
have been formerly associated to central nervous system
anomalies [3, 6]. This evidence confirms how difficult it is
to predict the phenotype in case of mosaic genetic defects.
This is also true for the present patient where a reverse
situation has been observed, with a relatively mild pheno-
type associated to a significant percentage of blood cells
carrying the chromosomal anomaly (~ 40%). By contrast,
the observation of a very low-rate mosaicism (0.4%) or the
lack of 13q deletion in a tissue with a different embryonic
origin, such as the buccal epithelium, allowed us to
hypothesize a similar mosaic status likely in all the organs
with the same ectodermal origin, such as the brain, which
may underlie the patient’s normal neurodevelopment and
mild neurological signs [1–6]. Similarly, the absence of
13q deletion or low rate mosaicism might explain the lack
of eye tumor, even if retinoblastoma is not a constant
feature in association to germline13q deletions involving
RB1 [1–6], and a meta-analysis study showed no differ-
ence between children with mosaic and non-mosaic 13q
deletion [24]. However the mosaicism has been assessed
mostly on blood or fibroblast cells, both of mesenchymal
origin [24].
In our opinion, a better definition of genotype-phenotype
correlation in case of 13q14 mosaicism, may be achieved
evaluating different tissues on multiple patients. It would be
ideal to evaluate the mosaic status of a tissue of the same
embryonic origin of retina to search for a correlation
between the rate of mosaic deletion and retinoblastoma
outcome.
Oncologic surveillance may benefit from a precise
mosaicism rate assessment on tissues with a different
embryonic origin, which is especially relevant in all those
mosaic chromosomal conditions involving the deletion
of a tumor-suppressor gene, like RB1 in this case. In our
case, the risk to develop tumors of ectodermal origin,
may be considered very low, which is consistent with his
overcoming childhood without retinoblastoma outcome.
An increased risk of sarcoma, which is of mesodermal
origin like blood, cannot be completely ruled out.
Nevertheless, sarcoma (either soft tissue or bone
sarcoma) in hereditary retinoblastoma patients is
generally reported as a second tumor subsequent to
chemotherapy/radiotherapy [25]. Thus, the patient has
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been only recommended to avoid unnecessary radi-
ation exposure and, in the absence of specific symp-
toms, undergo a periodical physical examination.
Interestingly, very low-level ectodermal mosaicism
may also imply a small percentage of germinal cells
carrying the deletion, thus resulting in a low repro-
ductive risk. In addition, it may also explain why the
deletion here described was not prenatally detected
during amniocentesis, as amniotic cells, which are as-
sumed to closely reflect the karyotype of the fetus,
are most of ectodermal origin [26].
In conclusion, the patient reported here confirms that
the mosaic status, also of large chromosomal rearrange-
ments, can considerably modulate the phenotype associ-
ated to constitutional genetic defects. The assessment of
mosaicism rate in more than one tissue of different em-
bryonic origin may enhance genotype-phenotype correl-
ation. In addition, the present case underlies that
amniocentesis misdiagnosis is a concrete eventuality in
patients bearing low level fetal chromosomal mosaicism,
which cannot be easily identifiable in the absence of
ultrasound indications.
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